Quick Dispatch:
Your eccogene glp-1 AstraZeneca targets obesity market with Eccogene partnership orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eccogene glp-1 AstraZeneca targets obesity market with Eccogene partnership ships.
Need Help?
Questions about eccogene glp-1 AstraZeneca targets obesity market with Eccogene partnership, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eccogene glp-1 AstraZeneca targets obesity market with Eccogene partnership in your area.
Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases
27.46
Eccogene will present Phase 1b data for elecoglipron (AZD5004/ECC5004), our investigational oral small-molecule GLP-1 receptor agonist, in a late-breaking poster presentation at the American Diabetes…
21.92
AstraZeneca buys rights to GLP-1 drug from Eccogene for $185M upfront
20.55
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
22.04
AstraZeneca stays in GLP-1 drug race with new deal
24.65
The outlook for obesity from 2026 to 2030
22.24
AstraZeneca raises stakes in obesity drug race with Eccogene deal
22.86
